newsfilter
← Latest News
GlobeNewswire·

Interim Data from Ambrx's Study of ARX788 selected for Spotlight Poster Discussion at the 2022 San Antonio Breast Cancer Symposium

SAN DIEGO, Nov. 29, 2022 (GLOBE NEWSWIRE) -- ​Ambrx Biopharma Inc., or Ambrx, (NYSE:AMAM), a clinical stage biopharmaceutical company using its proprietary Engineered Precision Biologics (EPBs) platform to create